Skip to search boxSkip to navigationSkip to main content

Peptic ulcer disease

  • M. H. Ebell(corresponding author)
*Corresponding author for this work
  • Wayne State University
Scholary Output:
Contribution to journal
Review article
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Peptic ulcer disease affects between 5 percent and 10 percent of Americans during their lifetime. There are a variety of predisposing factors, including nonsteroidal anti-inflammatory drug (NSAID) use, Helicobacter pylori infection, tobacco use and, possibly, certain dietary practices. While H2- receptor antagonists remain the mainstay of therapy, the selection of an antiulcer drug should be individualized. Famotidine is preferred in persons who use alcohol, sucralfate may be preferred for maintenance therapy in smokers and omeprazole is useful in hypersecretors of acid and in patients with resistant ulcers. Antacids remain an effective treatment for uncomplicated duodenal ulcer in motivated patients. Eradication of H. pylori using a bismuth preparation plus one or two antibiotic agents should be considered in patients who have frequent recurrences and evidence of infection. Finally, risk factors such as tobacco or NSAID use should be modified whenever possible to reduce the risk of ulcer recurrence.

Publication Information

Output type

Scholary Output:
Contribution to journal
Review article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 217-227 (11 pages)

Journal (Volume, Issue Number)

American family physician (Volume 46, Issue 1)

Publication milestones

  • Published - 1992

Publication status

Published - 1992

ISSN

0002-838X

Publication IDs

  • Scopus: 0026631407
  • PubMed: 1621633

Publication metrics

Metrics

Scopus
citations
Fractional count
1
Fractional count
1
Fractional count
1
Fractional count
1

PlumX

Citation count
14
Captures
20